All in: Novartis adds another drug to its fast-growing radiopharmaceuticals division

[cafead]

via Just weeks after the pharma giant snapped up Endocyte and its radioisotope drug Lu-PSMA-617 in a $2.1 billion deal — adding it to the Advanced Accelerator Applications group it acquired a little more than a year ago for $3.9 billion — its dealmaking crew has added global rights to a new radiopharmaceutical called FF-10158 for oncology indications.

article source